The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

The Association of Real Estate Funds (AREF), the British Property Federation (BPF) and the Investment Property Forum (IPF) ...

“This will significantly modernise IPF’s Brisbane PDC capability, enabling us to meet our customers’ expectations well into the future. “The decision to relocate the PDC allows us to progress our ...

Living with IPF is never dull, says columnist Sam Kirton, who shares some updates on topics he's discussed in recent columns.

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...

The Boards of the Association of Real Estate Funds (AREF), the British Property Federation (BPF) and the Investment Property ...

A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...

Investors were quick to overlook the negatives. The post ASX 200 consumer stock surges despite loss and dividend cut appeared ...

Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life. Delays in treatment can result in advanced disease stages, reduced treatment ...

The British Property Federation, the Association of Real Estate Funds and the Investment Property Forum are in merger talks.

Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...